New drug duo aims to stop aggressive breast Cancer's return

NCT ID NCT05973864

Summary

This study is for people with triple-negative breast cancer who still have cancer cells after initial chemo-immunotherapy and surgery. It tests if adding the pill capecitabine to the immunotherapy pembrolizumab after surgery is better at preventing the cancer from coming back than pembrolizumab alone. The main goal is to see if this combination helps patients live longer without their cancer returning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHD Vendee

    RECRUITING

    La Roche-sur-Yon, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • CHU Amiens Picardie_Site Sud

    RECRUITING

    Amiens, 80054, France

    Contact Email: •••••@•••••

    Contact

  • CHU Bretonneau

    RECRUITING

    Tours, 37000, France

    Contact Email: •••••@•••••

    Contact

  • CHU Jean Minoz

    RECRUITING

    Besançon, France

    Contact Email: •••••@•••••

    Contact

  • Centre François Baclesse

    RECRUITING

    Caen, 14000, France

    Contact Email: •••••@•••••

    Contact

  • Centre Georges-François Leclerc

    RECRUITING

    Dijon, France

    Contact Email: •••••@•••••

    Contact

  • Centre Hospitalier de la Côte Basque

    RECRUITING

    Bayonne, 64109, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69008, France

    Contact Email: •••••@•••••

    Contact

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

    Contact

  • Centre Paul Strauss

    RECRUITING

    Strasbourg, France

    Contact Email: •••••@•••••

    Contact

  • Clinique Mutualiste de l'Estuaire

    RECRUITING

    Saint-Nazaire, France

    Contact Email: •••••@•••••

    Contact

  • Clinique de La Croix du sud

    RECRUITING

    Quint-Fonsegrives, 31130, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Claudius Regaud, IUCT Oncopole

    RECRUITING

    Toulouse, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Curie

    RECRUITING

    Paris, 75005, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Curie

    RECRUITING

    Saint-Cloud, 92210, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Godinot

    RECRUITING

    Reims, 51100, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, 13009, France

    Contact Email: •••••@•••••

    Contact

  • Institut Sainte Catherine

    RECRUITING

    Avignon, 84918, France

    Contact Email: •••••@•••••

    Contact

  • Institut de Cancérologie de Lorraine

    RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Polyclinique Bordeaux Nord Aquitaine

    RECRUITING

    Bordeaux, 33077, France

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.